Salbutamol: Short-acting beta-2 agonist for bronchospasm and asthma relief
Salbutamol (also known as albuterol in North America) is a short-acting selective beta-2 adrenoceptor agonist (SABA) and one of the most widely used bronchodilator drugs worldwide. Since its introduction in the 1960s, it has become the cornerstone of acute relief therapy in asthma and the most commonly used rescue inhaler globally. Salbutamol is available under various trade names including Ventolin, Sultanol, and many generics.
As a rescue medication, salbutamol provides rapid bronchodilation within minutes. It is used both as a metered-dose inhaler (MDI) and as a solution for nebulisation in severe attacks. In asthma management, salbutamol represents the relief arm of therapy, while long-term control relies on inhaled corticosteroids and, in more severe disease, long-acting beta-2 agonists.
Mechanism of Action
Salbutamol selectively stimulates beta-2 adrenoceptors on bronchial smooth muscle cells. Receptor activation leads to stimulation of adenylate cyclase, increasing intracellular cyclic AMP (cAMP). Elevated cAMP activates protein kinase A, which phosphorylates and inactivates myosin light-chain kinase, leading to smooth muscle relaxation and bronchodilation. This mechanism produces rapid, reversible dilation of both large and small airways.
Additional effects include stimulation of mucociliary clearance, inhibition of mediator release from mast cells, and relaxation of uterine smooth muscle (relevant in preterm labour). Salbutamol is approximately 100 times more selective for beta-2 than beta-1 receptors, which minimises cardiac stimulation at therapeutic doses, though cardiovascular effects become more pronounced at higher doses.
Indications
- Acute bronchospasm relief: Rescue therapy in asthma attacks and acute bronchoconstriction
- Exercise-induced bronchoconstriction: Pre-exercise inhalation to prevent exercise-induced narrowing of the airways
- COPD acute exacerbation: Bronchodilation as part of acute management alongside ipratropium
- Acute severe asthma (emergency): High-dose nebulisation, sometimes combined with ipratropium
- Hyperkalaemia: Intravenous or nebulised salbutamol transiently shifts potassium into cells; used in emergency management of severe hyperkalaemia
- Preterm labour: Intravenous tocolysis to inhibit uterine contractions (specialised use)
Dosage and Administration
Inhaled relief therapy (MDI): 100 to 200 micrograms (1 to 2 puffs) as needed; up to 4 times per day for symptom relief. Acute severe asthma (nebuliser): 2.5 mg to 5 mg via nebuliser every 20 to 30 minutes in an emergency setting; repeat doses as clinically indicated. Exercise prophylaxis: 200 micrograms 15 to 30 minutes before exercise.
Correct inhaler technique is crucial: the MDI should be shaken, and inhalation should be slow and deep with a 10-second breath hold. A spacer device significantly improves drug delivery, especially in children and during acute attacks when coordination is difficult. Nebuliser solution (2.5 mg/2.5 ml) should not be diluted unless specifically required by the device.
Side Effects
Common: Tremor (particularly of the hands — due to beta-2 stimulation of skeletal muscle), tachycardia and palpitations (beta-1 spillover at higher doses), headache, dizziness, nervousness.
Metabolic: Hypokalaemia — salbutamol drives potassium into cells via beta-2 receptor stimulation; clinically relevant at high doses or in nebulised form; monitor electrolytes in severe attacks. Mild hyperglycaemia can occur. Lactic acidosis has been reported with high-dose intravenous use.
Paradoxical bronchospasm: Rare but important — inhalation may trigger bronchoconstriction rather than relief, particularly with first use of a new inhaler. An alternative bronchodilator should be used if this occurs.
Interactions
- Non-selective beta-blockers (propranolol, nadolol): Block the bronchodilatory effect of salbutamol; contraindicated in asthma; use cardioselective beta-1 blockers with caution if absolutely necessary
- Corticosteroids, diuretics, and xanthines (theophylline): May enhance hypokalaemic effect of salbutamol; monitoring of potassium levels required
- MAO inhibitors and tricyclic antidepressants: Potentiate cardiovascular effects of salbutamol; caution required
- Digoxin: Salbutamol-induced hypokalaemia may increase the risk of digoxin toxicity; potassium monitoring important
- Other sympathomimetics: Additive cardiovascular effects; avoid unnecessary combinations
Special Notes
Overuse as a warning sign: Increasing reliance on salbutamol as a rescue inhaler (more than 2 days per week, or running out of rescue inhalers frequently) is a marker of poorly controlled asthma and should prompt review of the maintenance regimen rather than simply increasing salbutamol use. GINA guidelines recommend using an ICS-containing reliever in some patients.
Pregnancy: Salbutamol is considered safe in pregnancy, particularly via inhalation. It is used intravenously as a tocolytic in preterm labour. Monitor maternal heart rate and blood glucose. Neonatal hypoglycaemia is possible if high doses are administered close to delivery.
Inhaler technique: A spacer device is strongly recommended for all patients, especially children and the elderly. Poor inhaler technique is one of the most common reasons for suboptimal asthma control and should be assessed at every review.
Related Topics
- Salmeterol — Long-acting beta-2 agonist for maintenance therapy
- Budesonide — Inhaled corticosteroid, cornerstone of asthma maintenance
- Ipratropium — Short-acting anticholinergic bronchodilator
- All active ingredients overview
Frequently Asked Questions
How quickly does salbutamol work?
When inhaled correctly, salbutamol begins to work within 3 to 5 minutes. Maximum bronchodilatory effect is reached after approximately 15 to 30 minutes. The effect typically lasts 4 to 6 hours.
Why does salbutamol cause tremor?
Salbutamol stimulates beta-2 receptors not only in bronchial smooth muscle but also in skeletal muscle. This stimulation of muscle beta-2 receptors causes an increase in contractile tremor frequency, perceived as a fine shaking particularly in the hands. This effect is dose-dependent and usually disappears as tolerance develops or the dose is reduced.
Is a spacer necessary with a salbutamol inhaler?
A spacer is not strictly necessary for most adults with good inhaler technique, but it substantially improves the fraction of the dose reaching the lungs and is strongly recommended for children, elderly patients, and all patients during acute attacks when coordination is compromised. It also reduces oropharyngeal deposition.